Journal article
Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review
Abstract
Importance: The non-vitamin K antagonist oral anticoagulants (NOACs) apixaban, dabigatran, edoxaban, and rivaroxaban are administered in fixed doses without anticoagulant monitoring. Randomized trials show that unmonitored NOAC therapy is at least as effective as and safer than dose-adjusted warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Subgroup analyses indicate that plasma drug levels or anticoagulant …
Authors
Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
Journal
JAMA Cardiology, Vol. 2, No. 5, pp. 566–574
Publisher
American Medical Association (AMA)
Publication Date
May 1, 2017
DOI
10.1001/jamacardio.2017.0364
ISSN
2380-6583